Holland Capital has sold Quantib to RadNet
Quantib B.V., a portfolio company of Holland Capital, has been sold to RadNet, Inc.
Founded in 2012 and headquartered in the Netherlands, Quantib is a leading radiology artificial intelligence and machine learning company focusing on clinical solutions for prostate cancer and neurodegeneration.
RadNet is a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 350 owned and operated outpatient imaging centers in the USA.
Holland Capital is one of the first independent private equity firms in the Netherlands. Since 1981, they have been successfully and responsibly investing in promising small and medium-sized Dutch businesses with growth ambitions. With a clear investment strategy, they anticipate long-term trends in attractive growth markets, focusing on the healthcare and technology sectors. Their experienced and dedicated investment team knows what entrepreneurship is.
One of Oaklins’ teams in the USA served as the exclusive financial advisor to Quantib B.V.
Falar com a equipa da transação
James McLaren
Oaklins TM Capital
Michael S. Goldman
Oaklins TM Capital
Michael L. Bauman
Oaklins TM Capital
Harrison P. Boeschenstein
Oaklins TM Capital
Transações relacionadas
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Saber maisDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Saber maisXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Saber mais